BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/22/2020 6:23:06 AM | Browse: 910 | Download: 1882
 |
Received |
|
2020-06-12 11:10 |
|
Peer-Review Started |
|
2020-06-12 11:11 |
|
First Decision by Editorial Office Director |
|
2020-07-30 23:32 |
|
Return for Revision |
|
2020-07-30 23:32 |
|
Revised |
|
2020-08-24 10:12 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-09-01 11:08 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-09-01 20:42 |
|
Articles in Press |
|
2020-09-01 20:42 |
|
Edit the Manuscript by Language Editor |
|
2020-09-06 01:28 |
|
Typeset the Manuscript |
|
2020-09-18 17:42 |
|
Publish the Manuscript Online |
|
2020-09-22 06:23 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Respiratory System |
| Manuscript Type |
Minireviews |
| Article Title |
Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapies for lung damage caused by COVID-19
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Aleksandra Klimczak |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Aleksandra Klimczak, DSc, PhD, Full Professor, Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy Polish Academy of Sciences, Rudolfa Weigla 12, Wrocław 53-114, Poland. aleksandra.klimczak@hirszfeld.pl |
| Key Words |
Mesenchymal stem cells; Stem/progenitor cells; Lung damage; Mesenchymal stem cell secretome; COVID-19 disease; COVID-19 pneumonia |
| Core Tip |
The new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has reached pandemic proportions, developing the coronavirus disease (COVID-19), which leads to the severe pneumonia. The lungs are the primary organ affected by SARS-CoV-2, with a very slow turnover for renewal. SARS-CoV-2 enters the lungs and induces immune response with cytokine storm and subsequent organ dysfunction. To date, there is no effective antiviral therapy for COVID-19. Cell-based therapy involving mesenchymal stem cells (MSCs) and/or their secretome is considered as a supportive therapy for critically ill COVID-19 patients. MSCs can regenerate severely injured respiratory tract cells through their trophic, anti-inflammatory, and immunomodulatory properties. |
| Publish Date |
2020-09-22 06:23 |
| Citation |
Klimczak A. Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapy in lung damage caused by COVID-19. World J Stem Cells 2020; 12(9): 1013-1022 |
| URL |
https://www.wjgnet.com/1948-0210/full/v12/i9/1013.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v12.i9.1013 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
